| scholarly article | Q13442814 |
| editorial | Q871232 |
| P356 | DOI | 10.1089/ARD.1994.4.67 |
| P698 | PubMed publication ID | 7950301 |
| P2093 | author name string | Krieg AM | |
| Stein CA | |||
| P433 | issue | 2 | |
| P304 | page(s) | 67-69 | |
| P577 | publication date | 1994-01-01 | |
| P1433 | published in | Antisense research and development | Q27709953 |
| P1476 | title | Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides | |
| P478 | volume | 4 |
| Q41736928 | A good antisense molecule is hard to find |
| Q77296867 | Activation of spleen lymphocytes by plasmid DNA |
| Q35285800 | Alternative for anti-TNF antibodies for arthritis treatment |
| Q38299925 | An experimental and theoretical study of the inhibition of Escherichia coli lac operon gene expression by antigene oligonucleotides |
| Q41526877 | Anti-oncogene Ribozymes for Cancer Gene Therapy |
| Q41526944 | Antisense Inhibition of Virus Infections |
| Q52173135 | Antisense approach for study of cell adhesion molecules in central nervous system. |
| Q30426495 | Antisense approaches to the gene therapy of cancer--'Recnac'. |
| Q47896067 | Antisense downregulation of SARS-CoV gene expression in Vero E6 cells |
| Q41702903 | Antisense methods for discrimination of phenotypic properties of closely related gene products: Jun kinase family |
| Q33916097 | Antisense oligonucleotides as a tool for gene functionalization and target validation |
| Q41883356 | Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression |
| Q50587585 | Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. |
| Q42442271 | Antisense oligonucleotides in neuroendocrinology: enthusiasm and frustration |
| Q38341158 | Antisense oligonucleotides: is the glass half full or half empty? |
| Q33607807 | Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides |
| Q41342193 | Antisense technology and prospects for therapy of viral infections and cancer |
| Q73727512 | Antisense therapy of influenza |
| Q42057726 | Application of antisense oligodeoxynucleotides for suppression of Na+/Ca2+ exchange. |
| Q38294480 | Application of antisense technology to therapeutics |
| Q40858027 | Bcl-X(L) antisense sensitizes human colon cancer cell line to 5-fluorouracil |
| Q45753100 | Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection |
| Q48534416 | Brain-derived neurotrophic factor antisense oligonucleotide impairs memory retention and inhibits long-term potentiation in rats |
| Q36192928 | Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides |
| Q38329058 | Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide |
| Q61735098 | Chapter 14 Using Antisense Technology to Study Mitosis |
| Q40397064 | Characterization of hybridization between synthetic oligodeoxynucleotides and RNA in living cells |
| Q48569299 | Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs |
| Q54445009 | Control of cytokine gene expression using small RNA interference: blockade of interleukin-10 and interferon-gamma gene expression in pig cells. |
| Q34307394 | CpG motifs in bacterial DNA trigger direct B-cell activation |
| Q41553589 | Critical issues in the antisense inhibition of brain gene expression in vivo: experiences targetting the 5-HT1A receptor. |
| Q73190582 | Design and efficacy of serotonin-2A receptor antisense oligodeoxynucleotide |
| Q36174842 | Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering |
| Q38343519 | Diazepam protects against rat hippocampal neuronal cell death induced by antisense oligodeoxynucleotide to GABA(A) receptor gamma2 subunit |
| Q38289866 | Does antisense exist? |
| Q40850718 | Drug discovery: past, present and future. |
| Q38353215 | Elucidation of gene function using C-5 propyne antisense oligonucleotides |
| Q33637644 | Gene therapy and vascular disease |
| Q64954162 | Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs. |
| Q73323687 | Highly loaded nanoparticulate carrier using an hydrophobic antisense oligonucleotide complex |
| Q41134788 | Improved oligonucleotide uptake and stability by a new drug carrier, the SupraMolecular Bio Vector (SMBV). |
| Q41184526 | In vitro and in vivo action of antisense RNA. |
| Q38291471 | Inhibition of High Affinity Basic Fibroblast Growth Factor Binding by Oligonucleotides |
| Q33634156 | Inhibition of Plasmodium falciparum malaria using antisense oligodeoxynucleotides |
| Q73887554 | Inhibition of type I procollagen production by tRNAVal CTE-HSP47 ribozyme |
| Q24805526 | Morpholino antisense oligonucleotides: tools for investigating vertebrate development |
| Q38361683 | Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. |
| Q39782719 | Native oligodeoxynucleotides specifically active against human immunodeficiency virus type 1 in vitro: a G-quartet-driven effect? |
| Q37079391 | Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses |
| Q37419563 | Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides. |
| Q33716194 | Pharmacology of antisense oligonucleotide inhibitors of protein expression |
| Q77334638 | Phosphorothioate oligodeoxyribonucleotides inhibit ribonuclease L thereby disabling a mechanism of interferon action |
| Q40814102 | Photodynamic antisense regulation of human cervical carcinoma cell growth using psoralen-conjugated oligo(nucleoside phosphorothioate). |
| Q41100801 | Potent and selective gene inhibition using antisense oligodeoxynucleotides |
| Q38355679 | Potent and selective inhibition of gene expression by an antisense heptanucleotide |
| Q36225146 | Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. |
| Q73101284 | Proteolipid protein regulates the survival and differentiation of oligodendrocytes |
| Q73765779 | Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides |
| Q97533602 | SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus |
| Q34062626 | Selecting optimal antisense reagents |
| Q70804641 | Sense, antisense, nonsense: where's the right way? |
| Q73369565 | Sensory regulation of immediate-early gene expression in mammalian visual cortex: implications for functional mapping and neural plasticity |
| Q38296643 | Sequence context of antisense RelA/NF-kappa B phosphorothioates determines specificity |
| Q29039090 | Silencing disease genes in the laboratory and the clinic |
| Q40393427 | Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cells |
| Q39476820 | Specific inhibition of coxsackievirus B3 translation and replication by phosphorothioate antisense oligodeoxynucleotides |
| Q73819754 | Specific inhibition of nitric oxide production in macrophages by phosphorothioate antisense oligonucleotides |
| Q28469349 | Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines |
| Q33955684 | Synthetic oligonucleotides as therapeutics: the coming of age. |
| Q44471855 | Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene. |
| Q33957440 | The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells |
| Q35115949 | The Quest for an Efficacious Antiviral for Respiratory Syncytial Virus |
| Q34407499 | The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism |
| Q28349648 | The experimental use of antisense oligonucleotides: a guide for the perplexed |
| Q46477875 | The state of the art in antisense research |
| Q71791174 | Toward a Broad-Based Antisense Technology |
| Q47785506 | Translational inhibition of messenger RNA of the human pi class glutathione S-transferase by antisense oligodeoxyribonucleotides |
| Q41137996 | Treatment of multidrug-resistant murine leukemia with antisense mdr1 oligodeoxynucleotides |
| Q42527690 | Treatment of vascular smooth muscle cells with antisense phosphorothioate oligodeoxynucleotides directed against p42 and p44 mitogen-activated protein kinases abolishes DNA synthesis in response to platelet-derived growth factor. |
| Q33916104 | Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments |
| Q36254793 | Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance |
| Q35116151 | Vascular complications and gene therapy |
| Q74552680 | Viral targets for antisense oligonucleotides: a mini review |
| Q58294801 | [11] Gene functional analysis in nervous system |
Search more.